|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
To identify HOXB13 transcriptional targets in metastatic PCs, we performed integrative bioinformatics analysis of differentially expressed genes (DEGs) in the proximity of the human prostate tumor-specific AR binding sites.
|
31273254 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
As second-generation androgen receptor antagonists have been increasingly used for treatment of castration-resistant stage metastatic prostate cancer, new onset of symptomatic epidural lipomatosis should be considered as a possible differential diagnosis, especially because the urinary symptoms of cauda equina compression may be improperly attributed to the primary prostate neoplasm.
|
30763756 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Here, we identified and characterized an AR circular RNA, called circAR3, that is widely expressed in PCa cell models and prostate tumors. circAR3 can be secreted into culture media of PCa cell lines and is detectable in the serum from mice bearing PCa xenografts.
|
31760376 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Our early detection efforts led to the identification of elevated levels of antiapoptotic protein, c-FLIP and its upstream regulatory factors such as androgen receptor (AR), recepteur d'origine nantais (RON), a receptor tyrosine kinase in human prostate tumors.
|
30859654 |
2019 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
These results identify HoxB13 as a pivotal upstream regulator of AR-V7-driven transcriptomes that are often cell context-dependent in CRPC, suggesting that HoxB13 may serve as a therapeutic target for AR-V7-driven prostate tumors.
|
29844167 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The results offer a mechanism-based therapeutic paradigm for disrupting the AR growth-promoting axis in the spectrum of prostate tumors while reducing global suppression of testosterone actions.
|
30185422 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Our findings reveal novel mechanisms of AR transcription, which is dynamically regulated in prostate tumor progression.
|
30027545 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Our study links AR expression heterogeneity to distinct castration/enzalutamide responses and has important implications in understanding the cellular basis of prostate tumor responses to AR-targeting therapies and in facilitating development of novel therapeutics to target AR<sup>-/lo</sup> PCa cells/clones.
|
30190514 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
These results suggest that blocking BMI1 alone or in combination with anti-AR therapy can be more efficient to suppress prostate tumor growth.
|
29402932 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
20(S)-protopanaxadiol regio-selectively targets androgen receptor: anticancer effects in castration-resistant prostate tumors.
|
29765513 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Expression of mRNA and protein of AR as well as its target gene prostate-specific antigen (PSA) was much higher in metastatic prostate tumors than in primary prostate tumors.
|
30142696 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Therapeutic
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
The role of AR-Vs and their possible modulation by steroid tissue levels in distinct types of prostate tumors needs to be elucidated to help guide the best clinical management of these diseases.
|
30028845 |
2018 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that the AR is also an immunological target antigen, recognized in patients with prostate cancer, and targetable by means of vaccines in rodent models with delays in prostate tumor growth.
|
28181678 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Furthermore, ADT combined with vaccination, specifically a DNA vaccine encoding the ligand-binding domain of the AR, led to improved antitumor responses as measured by tumor volumes and delays in the emergence of castrate-resistant prostate tumors in two murine prostate cancer models (Myc-CaP and prostate-specific PTEN-deficient mice).
|
29051161 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
There was a significant increase in nuclear AR and activity in prostate tumors from castrate DNTGFβRII compared with TGFβRII WT mice.
|
28324007 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
We analyzed TCGA gene expression profiles of 497 prostate tumor samples according to 43 genes involved in EMT and 3 hormone receptor genes (AR, ESR1, ESR2) as well as clinical characteristic of cancer patients.
|
29206234 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
The androgen receptor (AR) plays important roles in prostate cancer development and prostate tumor growth.
|
28783103 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
GRHL2 colocalized with AR in prostate tumors and was frequently amplified and upregulated in prostate cancer.
|
28473532 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
GeneticVariation
|
group |
BEFREE |
CDK4/6i was also effective in prostate tumor models expressing the AR-V7 variant or the AR F876L mutation, both of which are associated with treatment resistance.
|
28209757 |
2017 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Here, we describe the development, characterization, and utilization of a novel human LNCaP prostate tumor cell line, N-AR, which stably expresses wild-type AR tagged at its N terminus with the streptavidin-binding peptide epitope (streptavidin-binding peptide-tagged wild-type androgen receptor; SBP-AR).
|
27365400 |
2016 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Together, these data indicate AR serves as a key modulator of PPARγ expression and function within prostate tumors..
|
26945682 |
2016 |
|
Prostatic Neoplasms
|
0.600 |
Biomarker
|
group |
BEFREE |
Moreover, androgen and its cognate receptor, androgen receptor (AR), regulate various signaling pathways for prostate tumor growth.
|
26685282 |
2016 |
|
Prostatic Neoplasms
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Aberrant coexpression of AR and hnRNPH1 and downregulation of miR-212 were detected in prostate tumors and correlate with disease progression in AA men compared with CA men.
|
26553749 |
2016 |